3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Myeloid
1
Lymphoid
1
Classical hematology
1
Conditions
Myelodysplastic Syndromes
87
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
71
Leukemia, Myeloid, Acute
66
Leukemia
64
Myeloproliferative Disorders
60
Precursor Cell Lymphoblastic Leukemia-Lymphoma
45
Primary Myelofibrosis
39
Leukemia, Myeloid, Chronic-Phase
39
Leukemia, Myelomonocytic, Chronic
38
Polycythemia Vera
32
Lymphoma, Non-Hodgkin
29
Lymphoma
29
Multiple Myeloma
28
Leukemia, Lymphocytic, Chronic, B-Cell
28
Hodgkin Disease
27
Lymphoma, Large B-Cell, Diffuse
26
Lymphoma, Mantle-Cell
25
Burkitt Lymphoma
25
Leukemia, Myeloid, Accelerated Phase
24
Lymphoma, Large-Cell, Immunoblastic
23
Lymphoma, Follicular
23
Lymphoma, B-Cell, Marginal Zone
23
Blast Crisis
23
Thrombocythemia, Essential
20
Lymphoma, T-Cell, Cutaneous
19
Leukemia, Hairy Cell
18
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
17
Anemia, Refractory, with Excess of Blasts
17
Neoplasms, Plasma Cell
16
Myelodysplastic-Myeloproliferative Diseases
16
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hemorrhagic Disorders
×
Myeloid
×
Clear all
NCT02055781
2021-11-18
PAC326
CTI BioPharma
Phase 3
Terminated
311 enrolled
12 charts